Detalhe da pesquisa
1.
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.
Lancet Oncol
; 24(5): 443-456, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37142371
2.
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
Lancet
; 399(10323): 447-460, 2022 01 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-34953525
3.
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).
Int J Cancer
; 151(3): 422-434, 2022 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35411939
4.
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial.
PLoS Med
; 19(6): e1003998, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35671327
5.
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.
Lancet Oncol
; 21(1): 162-174, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31806540
6.
Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial.
J Clin Oncol
; 40(8): 825-836, 2022 03 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34757812
7.
Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial.
JNCI Cancer Spectr
; 6(4)2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35877084
8.
Docetaxel chemotherapy for metastatic hormone refractory prostate cancer as first-line palliative chemotherapy and subsequent re-treatment: Birmingham experience.
Oncol Rep
; 20(4): 891-6, 2008 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-18813832
9.
Assessment of the feasibility of using transrectal ultrasound for postimplant dosimetry in low-dose-rate prostate brachytherapy.
Med Dosim
; 41(4): 290-295, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27623391
10.
What Predicts Minimal Response to Abiraterone in Metastatic Castrate-resistant Prostate Cancer?
Anticancer Res
; 35(10): 5615-21, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26408734
11.
Time to prostate specific antigen (PSA) nadir may predict rapid relapse in men with metastatic castration-resistant prostate cancer (CRPC) receiving docetaxel chemotherapy.
Med Oncol
; 30(4): 719, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24026658